VERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA (VRTX): 50 pipeline candidates · 22 upcoming catalysts · ~18 mo cash runway · 65 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.5 months
D/E 0.37 · 1% dilution
Lead: Approved
50 candidates
22 upcoming, next in ~9d
0 buys · 65 sells (180d)
A transparent, data-derived signal for VERTEX PHARMACEUTICALS INC / MAacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$116.5B
Cash
$5.5B
Quarterly Burn
$1.5B
Runway
17.5 mo
Revenue
$3.0B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (50 candidates)
| Drug | Phase |
|---|---|
| abiraterone | Phase 1/Phase 2 |
| alyftrek | Approved |
| alyftrek | Approved |
| biological/vaccine | Phase 3 |
| bupropion | Phase 1 |
| cemiplimab | Phase 1/Phase 2 |
| cpi-1205 | Phase 1/Phase 2 |
| ctx001 | Phase 2/Phase 3 |
| drsp/ee | Phase 1 |
| elx/tez/iva | Phase 3 |
Showing 10 of 50 candidates. Sign up for full pipeline.
Upcoming Catalysts (22)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,683
Total value held
$83.06B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 33,025,620 | $14.75B |
| blackrock, inc. | 23,969,517 | $10.70B |
| state street corp | 11,730,139 | $5.24B |
| geode capital management, llc | 6,139,621 | $2.73B |
| vanguard portfolio management llc | 5,145,609 | $2.30B |
| janus henderson group plc | 4,263,054 | $1.90B |
| alliancebernstein l.p. | 3,910,786 | $1.77B |
| wellington management group llp | 3,212,589 | $1.43B |
| morgan stanley | 3,188,881 | $1.42B |
| ubs am, a distinct business unit of ubs asset management americas llc | 3,057,396 | $1.37B |
Showing top 10 of 1,683 institutional holders of VERTEX PHARMACEUTICALS INC / MA. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in VERTEX PHARMACEUTICALS INC / MA's pipeline?
VERTEX PHARMACEUTICALS INC / MA (VRTX) has 50 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is VERTEX PHARMACEUTICALS INC / MA's lead drug candidate?
VERTEX PHARMACEUTICALS INC / MA's most advanced tracked candidate is abiraterone (Phase 1/Phase 2) for Metastatic Castration Resistant Prostate Cancer (mCRPC).
What is VERTEX PHARMACEUTICALS INC / MA's next catalyst?
VERTEX PHARMACEUTICALS INC / MA's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: APLENZIN" — expected June 27, 2026.
What is VERTEX PHARMACEUTICALS INC / MA's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, VERTEX PHARMACEUTICALS INC / MA has approximately 17.5 months of cash runway.
What is VERTEX PHARMACEUTICALS INC / MA's market capitalization?
VERTEX PHARMACEUTICALS INC / MA's market capitalization is approximately $116.5B.
Get the full picture on VERTEX PHARMACEUTICALS INC / MA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.